Moderna, Inc.: Is Its mRNA Platform Fueling A Multi-Billion-Dollar Pipeline Beyond COVID?

Moderna reported its financial results for the fourth quarter and the full year of 2024, revealing both opportunities and challenges. The company recorded total revenue of $3.2 billion for the year, a 53% decrease from 2023, attributed largely to declining product sales. The net loss for 2024 was $3.6 billion, a slight improvement from a $4.7 billion net loss in 2023. Despite the reduction in revenue, Moderna ended the year with $9.5 billion in cash and investments, an increase reflecting strong operational cash management.